Abstract
Cognitive remediation (CR) has been found to improve cognitive performance among adults with schizophrenia in randomized controlled trials (RCTs). However, improvements in cognitive performance are often observed in the control groups of RCTs as well. There has been no comprehensive examination of change in control groups for CR, which may inform trial methodology and improve our understanding of measured outcomes for cognitive remediation. In this meta-analysis, we calculated pre–post change in cognitive test performance within control groups of RCTs in 32 CR trials (n = 794 participants) published between 1970 and 2011, and examined the association between pre–post change and sample size, duration of treatment, type of control group, and participants’ age, intelligence, duration of illness, and psychiatric symptoms. Results showed that control groups in CR trials showed small effect size changes (Cohen’s d = 0.12 ± 0.16) in cognitive test performance over the trial duration. Study characteristics associated with pre–post change included participant age and sample size. These findings suggest attention to change in control groups may help improve detection of cognitive remediation effects for schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage P. The role of randomization in clinical trials. Statistics in Medicine. 1(4):345–52, 1982.
Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, et al. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clinical Pharmacokinetics. 51(4):261–75, 2012. doi:10.2165/11598460-000000000-00000.
Alphs L, Benedetti F, Fleischhacker WW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? International Journal of Neuropsychopharmacology. 15:1–12, 2012. doi:10.1017/S1461145711001738.
Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues in Clinical Neuroscience. 13(2):155–172, 2011.
McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. The American Journal of Psychiatry. 164(12):1791–1802, 2007. doi:10.1176/appi.ajp.2007.07060906.
Grynszpan O, Perbal S, Pelissolo A, Fossati P, Jouvent R, Dubal S, et al. Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a meta-analytical study. Psychological Medicine. 41(1):163–173, 2011. doi:10.1017/S0033291710000607.
Tsai J, Stroup TS, Rosenheck RA. Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: A descriptive study. Journal of Community Psychology 39(1);76–88, 2011.
Wykes T, Huddy V. Cognitive remediation for schizophrenia: it is even more complicated. Current Opinion in Psychiatry. 22(2):161–167, 2009. doi:10.1097/YCO.0b013e328322fbf4.
Torrey EF: Surviving Schizophrenia: A Manual for Families, Consumers, and Providers. 4th edn. New York, Harper-Collins, 2001.
Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. The American Journal of Psychiatry. 168(5):472–485, 2011. doi:10.1176/appi.ajp.2010.10060855.
Cahill J, Barkham M, Hardy G, Rees A, Shapiro DA, Stiles WB, et al. Outcomes of patients completing and not completing cognitive therapy for depression. The British Journal of Clinical Psychology. 42(Pt 2):133–143, 2003. doi:10.1348/014466503321903553.
Thalheimer W, Cook S. How to Calculate Effect Sizes From Published Research Articles: A Simplified Methodology. 2002.
Marín-Martínez F, Sánchez-Meca J. Weighting by inverse variance or by sample size in random-effects meta-analysis. Educational and Psychological Measurement. 70(1):56–73, 2010. doi:10.1177/0013164409344534.
Kontis D, Huddy V, Reeder C, Landau S, Wykes T. Effects of age and cognitive reserve on cognitive remediation therapy outcome in patients with schizophrenia. The American Journal of Geriatric Psychiatry. 2012. doi:10.1097/JGP.0b013e31824877d7.
McGurk SR, Mueser KT. Response to cognitive rehabilitation in older vs. younger persons with severe mental illness. American Journal of Psychiatric Rehabilitation. 11:90–105, 2008.
Reeder C, Newton E, Frangou S, Wykes T. Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program. Schizophrenia Bulletin. 30(1):87–100, 2004.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsa F, Lopez-Carrilero R, et al. REPYFLEC cognitive remediation group training in schizophrenia: Looking for an integrative approach. Schizophrenia Research. 2012. doi:10.1016/j.schres.2012.08.035.
Bark N, Revheim N, Huq F, Khalderov V, Ganz ZW, Medalia A. The impact of cognitive remediation on psychiatric symptoms of schizophrenia. Schizophrenia Research. 63(3):229–235, 2003.
Vinogradov S, Fisher M, Nagarajan S. Cognitive training in schizophrenia: golden age or wild west? Biological Psychiatry. 73(10):935–937, 2013. doi:10.1016/j.biopsych.2013.03.015.
Conflict of interest
Dr. Radhakrishnan has received funding from the APIRE/ Janssen Pharmaceutical Resident Psychiatric Research Scholar Fellowship and NIMH R25 IMPORT training grant (R25MH071584). Dr. Tsai has received funding from the Bristol Meyers Squibb Foundation. But none of the authors report any conflicts of interest with this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Radhakrishnan, R., Kiluk, B.D. & Tsai, J. A Meta-analytic Review of Non-specific Effects in Randomized Controlled Trials of Cognitive Remediation for Schizophrenia. Psychiatr Q 87, 57–62 (2016). https://doi.org/10.1007/s11126-015-9362-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-015-9362-6